0 89

Cited 0 times in

Chapter 19 - Intravesical Chemotherapy

Authors
Kim, SI; Choo, SH
Publication Year
2018
Citation
Bladder Cancer:263-276, 2018
Book Title
Bladder Cancer
ISBN
9780128099391
Abstract
Bacillus Calmette-Guérain (BCG) is the most potent intravesical agent but other intravesical agents are necessary for patients who have failed BCG or who are intolerant to the side effects of BCG. Many chemotherapeutic agents such as thiotepa, mitomycin C, doxorubicin, epirubicin and Gemcitabine are available. Intravesical chemotherapy reduces risk of recurrence, but does not appear to delay progression to muscle invasive cancer. Therefore, it is best indicated in moderate risk patients. Differences of efficacy in risk of recurrence and progression are not significant between agents. Side effects are usually mild and self-limited, but extravasation of chemotherapeutic agent can lead to severe inflammation and necrosis. Novel methods of drug administration such as local microwave-induced hyperthermia and electromotive drug administration are introduced to improve suboptimal effect of intravesical chemotherapy. Some studies showed promising results of these methods with lower recurrence and lower progression rates compared to intravesical chemotherapy alone.
Keywords
Intravesical chemotherapynon-muscle invasive bladder cancerthiotepamitomycin Cdoxorubicinepirubicingemcitabine
DOI
10.1016/B978-0-12-809939-1.00019-9
Appears in Collections:
Others > Book > Book
AJOU Author
김, 선일추, 설호
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse